B. M. Tyler

Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression.

C. L. Douglas, K. Jansen, E. Richelson, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol

E. Richelson, A. Fauq, D. Mccormick, 2000, Brain Research.

In vitro binding and CNS effects of novel neurotensin agonists that cross the blood–brain barrier

Y. Pang, C. L. Douglas, E. Richelson, 1999, Neuropharmacology.

Synthesis of (2S)-2-amino-3-(1H-4-indolyl)propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides

E. Richelson, A. Fauq, B. Cusack, 1998 .

Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception

C. L. Douglas, E. Richelson, B. Cusack, 1998, Brain Research.

In vivo studies with low doses of levocabastine and diphenhydramine, but not pyrilamine, antagonize neurotensin-mediated antinociception

E. Richelson, B. Cusack, K. Groshan, 1998, Brain Research.

Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo

E. Richelson, D. Mccormick, B. Cusack, 1998, FEBS letters.